The FDA has granted fast track designation to Apellis Pharmaceuticals’ APL-2 as monotherapy for treatment of geographic atrophy, according to a company press release.
A fast track designation will expedite both the development and review of APL-2, a complement factor C3 inhibitor.
“The fast track designation represents an important recognition by the FDA of APL-2’s potential to treat geographic atrophy, a blinding disease for which there is no treatment,” Apellis founder and CEO Cedric Francois, MD, PhD, said. “The severe vision loss associated with GA makes it
Uncategorized